SEHK:1167Biotechs
Jacobio Pharmaceuticals Group (SEHK:1167) Loss Narrows To C¥58.9m Challenging Bearish Narratives
Jacobio Pharmaceuticals Group (SEHK:1167) opened FY 2025 with first half revenue of C¥45.7 million and a basic EPS loss of C¥0.08, while trailing 12 month figures show revenue of C¥53.5 million and a basic EPS loss of about C¥0.19, underlining that the business is still in loss making territory on a full year view. The company has seen revenue move from C¥155.7 million with basic EPS of C¥0.02 in 2H 2024 to C¥45.7 million with basic EPS of C¥0.08 loss in 1H 2025, against a trailing 12 month...